

Participants

- Members of the European Parliament
- Representatives of the European Commission and the EU Member States
- Stakeholder organisations including patients and health professionals associations
- Pharmaceutical and life science industries



Kindly supported by



Registration

Fax: +32 (0)2 284 91 49

E-mail:

jorgo.chatzimarkakis@europarl.europa.eu

for the European Life Science Circle

“The Informed Patient - What the European Union has to do”

on Thursday 6 December 2007

9.00 - 13.00

Location: European Parliament, Brussels, Room 3G3

Name: _____

Function: _____

Institution: _____

Address: _____

E-mail: _____

In case you don't have a permanent access pass to the European Parliament, please fill in the following information. This is required to get an access pass to the European Parliament.

Date of birth:

Please reply no later than 30 November 2007



The Informed Patient What the European Union has to do

European Parliament
Brussels - Room 3G3

Thursday 6 December 2007
9.00 - 13.00

**"The Informed Patient-
What the European Union has to do"**

8.30 Registration

9.00 Inaugural Address
Hans-Gert PÖTTERING, President of the European Parliament (tbc)

9.10 Introduction
Françoise GROSSETÊTE
Member of the European Parliament

9.25 1st Session: Expectation of society
Chair: Jorgo CHATZIMARKAKIS
Member of the European Parliament

Panel Discussion with the participation of:

- § Anders OLAUSON, President, European Patients' Forum (EPF)
- § Jim MURRAY, Former Director General, The European Consumers' Organisation (BEUC)
- § Daniel MART, President, Standing Committee of European Doctors (CPME)
- § Leopold SCHMUDERMAIER, President, Pharmaceutical Group of the European Union (PGEU)
- § Brian AGER, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
- § Hubertus CRANZ, Director General, Association of the European Self-Medication Industry (AESGP)

10.45 Break

11.00 2nd Session: What legal framework can we build in Europe?

Chair: Dagmar ROTH-BEHRENDT,
Member of the European Parliament

Panel Discussion with the participation of:

- § Robert MADELIN, Director General, DG Health and Consumer Protection, European Commission
- § Martin TERBERGER, Head of Unit Pharmaceuticals, DG Enterprise and Industry, European Commission
- § Noël WATHION, Head of Unit Post Authorisation, Evaluation of Medicines for Human Use, European Medicines Agency
- § Per MANELL, The Swedish Association of the Pharmaceutical Industry
- § Martin Clemens AUER, Head of Section, Austrian Ministry for Health, Family and Youth

12.30 Conclusion
Jorgo CHATZIMARKAKIS
Member of the European Parliament

12.45 Buffet



Background of the meeting

EU institutions, healthcare stakeholders and citizens seem to broadly agree that there are huge disparities across Europe in terms of accessibility and quality of health information, and that communication with patients and the general public on health issues and medicines should be enhanced with the objective of having better informed patients. However, concrete improvements of the current situation still need to be delivered.

The long-awaited European Commission's report on the provision of information to patients, as requested by the European Parliament and the Council in 2004, represents a unique opportunity to start developing a truly European health information strategy. This should help to reduce the current inequalities among different population groups and EU Member States in accessing high quality information throughout the so-called "patient journey" (prevention, early diagnosis, treatment, compliance).

Clearly, no single information source will be able to do the job alone. What is needed is a comprehensive approach involving various providers of high quality health information, for the benefit of "empowered" patients who increasingly demand a greater role in decisions affecting their own health.

The European Life Science Circle (ELSC) was launched in 2006 by Jorgo Chatzimarkakis, Member of the European Parliament (EP) to facilitate dialogue with interested stakeholders on relevant issues in the context of life science and pharmaceuticals. This event is co-hosted by the three EP representatives in the EU High Level Pharmaceutical Forum: Françoise Grossetête, Dagmar Roth-Behrendt and Jorgo Chatzimarkakis.